FY2024 EPS Estimates for CSL Limited Boosted by Analyst (OTCMKTS:CSLLY)

CSL Limited (OTCMKTS:CSLLY – Get Rating) – Investment analysts at Jefferies Financial Group boosted their FY2024 earnings per share estimates for CSL in a research report issued to clients and investors on Sunday, January 15th. Jefferies Financial Group analyst D. Stanton now forecasts that the company will post earnings per share of $3.24 for the year, up from their prior forecast of $3.20. Jefferies Financial Group has a “Buy” rating on the stock. The consensus estimate for CSL’s current full-year earnings is $2.74 per share. Jefferies Financial Group also issued estimates for CSL’s FY2025 earnings at $3.94 EPS.

Separately, Credit Suisse Group raised shares of CSL from a “neutral” rating to an “outperform” rating in a research report on Thursday, November 10th.

CSL Stock Performance

CSLLY stock opened at $101.32 on Wednesday. The business has a 50 day moving average price of $98.43 and a 200 day moving average price of $97.03. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.71 and a current ratio of 2.32. CSL has a fifty-two week low of $83.30 and a fifty-two week high of $105.44.

About CSL

(Get Rating)

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and CSL Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants.